Anthem (ANTM) Dragging Feet on Sarepta's (SRPT) Exondys 51 is Likely Negotiating Tactic - Oppenheimer
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Oppenheimer affirms Sarepta Therapeutics (Nasdaq: SRPT) at Outperform with a price target of $76 as Anthem said EXONDYS 51 wasn't medically necessary earlier today, putting pressure on SRPT shares.
The firm commented:
Anthem's medical policy took the position that eteplirsen (EXONDYS 51) is "investigational and not medically necessary," and it is not currently covered by Anthem. However, we remind investors that this is the third week of the EXONDYS 51 launch. While Sarepta has been able to quickly mitigate its negotiations with some large payers (Cigna, Humana, United Health), other discussions will take longer to conclude. We view this move by Anthem to be a negotiation tactic and not a final decision on reimbursement. Additionally, we note that there is an appeals process.
Anthem is one of the largest owners of Blue Cross Blue Shield plans, though sets its own drug formulary. Anthem has ~40 million members. We spoke with an Anthem rep today who said coverage decisions can change and there is an appeals process available through Anthem that either/both patients and physicians can go through to try to obtain access to drugs not covered, the firm noted.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sarepta Therapeutics (SRPT) Target of Cautious Article
- Equity and Commodity Markets
- Baxter (BAX) volatility flat on more calls than puts into Q3 and outlook
Create E-mail Alert Related CategoriesAnalyst Comments, Momentum Movers, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!